Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with...
Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with...
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva Decision follows negative opinion by the Committee for Medicinal...
European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva (FOP)Decision...
An FDA committee voted favorably on whether the available evidence supports the effectiveness of palovarotene for fibrodysplasia ossificans progressiva.
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million... | May 26, 2023